Rapport Therapeutics, Inc. Common Stock
RAPP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Market Cap | $3,679 | $3,760 | $4,184 |
| - Cash | $57 | $70 | $31 |
| + Debt | $1 | $2 | $10 |
| Enterprise Value | $3,624 | $3,692 | $4,164 |
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Gross Profit | -$1 | -$0 | -$0 |
| % Margin | – | – | – |
| EBITDA | -$77 | -$35 | -$10 |
| % Margin | – | – | – |
| Net Income | -$78 | -$35 | -$11 |
| % Margin | – | – | – |
| EPS Diluted | -0.38 | -0.19 | -0.053 |
| % Growth | -100% | -258.5% | – |
| Operating Cash Flow | -$65 | -$27 | -$3 |
| Capital Expenditures | -$2 | -$2 | -$0 |
| Free Cash Flow | -$67 | -$29 | -$4 |